Turmeric Based Therapy in the Treatment of Psoriasis: A Clinical Trial

Launched by ZAGAZIG UNIVERSITY · Aug 24, 2019

Keywords

ClinConnect Summary

Psoriasis is a prevalent skin disorder. It affects around 4% of world's population. It can be disfiguring and disabling in severe cases. There is dysregulated immune response in psoriatic patients to unknown injurious agents with upregulation of Th1/Th17 pathways which is mediated via Nuclear Factor kappa B (NFκB). NFκB is a key player in psoriasis development; its activation and nuclear translocation is present in every step of the way of psoriasis starting from keratinocyte release of cytokines -in response to stress- to the maturation and activation of dendritic cells, to the continuous ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with mild to moderate psoriasis vulgaris of any age \& gender.
• • 2. Patient didn't receive any systemic or topical therapy for psoriasis the last 4 weeks.
• Exclusion Criteria:
• • 1. Patients previously received topical or systemic therapy for psoriasis in the past 4 weeks.
• • 2. Patients with pustular or erythrodermic psoriasis.
• • 3. Patients with other dermatological diseases.
• • 4. Patients have hypersensitivity from the active ingredients of the therapy.